fibroblast growth factor (bFGF) was studied in the rat pituitary gland at light and electron microscopic levels using a specific monoclonal antibody. In the anterior lobe, bFGF-immunoreactivity was found mostly in a cell population without secretory granules, which was identified as the folliculo-stellate (FS) cell by its ultrastructure and expression of S-100 protein. The subcellular localization of the immunoreactivity in FS cell was strictly nuclear. Besides the FS cell, a minor cell population containing small granules of 60-100 nm diameter, which seemed to represent immature endocrine cells, was immunostained in the nuclei with the anti-bFGF antibody. In the intermediate lobe, a subpopulation of the S-100 protein-positive cells lining the pituitary cleft was immunoreactive for bFGF. These results imply that the agranular cell types are the main producer and/or target of rat pituitary bFGF, and that bFGF may play a role in the differentiation of pituitary endocrine cells.
Basic fibroblast growth factor (bFGF), also termed heparin-binding growth factor II or FGF-2, is a potent mitogen for cultured fibroblasts and many mammalian cell types of mesodermal and neuroectodermal origins (RIFKIN and MOSCATELLI, 1989) . Basic FGF, named for its basic pI, was originally purified from bovine pituitary gland as a single peptide with 146 amino acid residues and a molecular weight of 16,400 (ESCH et al., 1985) . The primary structure of bFGF is hihly conserved among mammals including the human, bovine and rat (RIFKINS and MOSCATELLI, 1989) . In addition to the pituitary gland, bFGF has been found in various normal and neoplasmic tissues, where it is thought to exert a wide spectrum of biological activities through paracrine and/or autocrine mechanisms (reviewed in GOSPODAROWICZ et al., 1987; BURGESS and MACIAG,1989) . However, there has been much controversy concerning the exact cellular and subcellular localizations of bFGF, including those in the pituitary gland where bFGF was originally purified. Recently, we developed a monoclonal antibody (bFM-1) against bFGF purified from the bovine brain, and confirmed its inhibitory effect on the growth of capillary endothelial cells in vitro (MATSUZAKI et al., 1989) . In the present study, we have applied this antibody to the rat pituitary gland for immunohistochemical localization of bFGF, at light and electron microscopic levels.
MATERIALS AND METHODS

Antibody
Monoclonal antibody against bovine brain bFGF (bFM-1) was obtained and purified as described previously (MATSUZAKI et al., 1989; YOSHITAKE et al., 1991) . This antibody was highly specific for bFGF from bovine, human and rodent sources and did not crossreact with acidic FGF. While bFM-1 recognized the conformation of the bFGF molecule necessary for its biological activity, it did not crossreact with denatured bFGF, and was unsuitable for an immunoblotting analysis.
Immunohistochemistry
Male Wistar rats at 10 weeks (300-350 g) were used in the present study. The animals were anesthetized by an intraperitoneal injection of sodium pentobarbital (50 mg/kg body weight) and sacrificed by bleeding from the heart. Pituitary glands were disseccted out and fixed by microwave irradiation for 90 sec in a cold 4% paraf ormaldehyde/0.1 M phosphate buffer (pH 7.2), followed by immersion in the same fixative for 4h at 4C. The tissue blocks, after being rinsed 270 0. AMANO et al.: overnight in the phosphate buffer containing 30 sucrose, were cut into 15m sections on a cryostat and mounted on glass slides coated with gelatin. The specimens were then incubated with bFM-1 (2 jig/ml) overnight at room temperature.
They were then treated for 1 h at room temperature with biotinylated anti-mouse IgG antibody (Vector) diluted with PBS (1:200). Normal rat serum was added at 2% to eliminate a nonspecific adsorption of the antibody to rat tissues. The sections were further incubated with avidin/biotinylated peroxidase complex (ABC) (Vector) for 1 h at room temperature. The site of immunoreaction was then made visible by 3', 3'-diaminobenzidine tetrahydrochloride.
For the double staining for bFGF and S-100 protein (S100), sections were incubated with a mixture of bFM-1 and rabbit anti-S100 antibody (1 :200; Dako) overnight and then reacted with mixture of biotinylated anti-mouse IgG and FITC-labeled anti-rabbit IgG (1: 20; Dako) for 1 h. After washing in PBS, the sections were first mounted in glycerol for observation under the fluorescence microscope and then washed again and further processed for ABC procedure.
For electron microscopic examination, the immunostained sections were fixed with 0.5% OsO4 in 0.1 M cacodylate buffer (pH 7.4) for 20 min, dehydrated and embedded in Epon 812. Ultrathin sections were made and examined with an electron microscope (Hitachi H-700) at 100 kV.
For the immunohistochemical control, bFM-1 was absorbed overnight with recombinant human bFGF (50 ng/ml) and used as the primary antibody.
RESULTS
In the rat pituitary sections immunostained with bFM-1, positive immunoreactions were recognized as described below (Fig. la) . When the sections were incubated with the preabsorbed antibody, no immunoreactivity was detectable in any cellular components, confirming the specificity of the bFGF-immunoreaction with bFM-1 (Fig. lb) .
Anterior lobe
Numerous cells exhibiting bFGF-immunoreactivity in their nuclei were distributed throughout the anterior lobe of pituitary gland. Some immunopositive cells formed small clusters, while others were present solitarily (Fig. 2) .
Immuno-electron microscopy demonstrated that most of the immunopositive cells were devoid of endocrine secretory granules and extended large cytoplasmic processes among the immunonegative endocrine cells (Fig. 3a) . Occasionally, a few adjacent immunopositive cells surrounded a small follicular cavity in which variable numbers of microvilli and cilia were protruded (Fig. 3b) . Junctional complexes were developed along the adjacent cell membranes. The ultrastructural characteristics made it possible to identify these immunoreactive agranular cells as folliculo-stellate (FS) cells (RENNELS, 1964; KUROSUMI, 1968) . In every immunoreactive cell, the reaction product appeared diffusely over the entire nucleus, without preferential localization in particular nuclear components. The cytoplasm was free of the immunoreaction.
Identification of the major type of bFGF-positive cells as the FS cell was further substantiated by its expression of S100, a marker protein for FS cells in rat anterior pituitary (NAKAJIMA et al., 1980; SHIRA-SAWA et al., 1983; LLOYD and MAILOUX, 1988) . When the same sections were double-stained for bFGF and S100, the nuclear immunoreactivity for bFGF and the cytoplasmic reactivity for S100 could be confirmed to coexist in most cells (Fig. 4a, b) . On counting a total of 200 immunopositive cells in 3 sections obtained from 3 individual anterior pituitaries, 90% of total bFGF-positive cells were found immunoreactive for S100, and 93% of total S100-positive FS cells immunoreactive for bFGF.
By immuno-electron microscopy, a small subpopulation of bFGF-immunoreactive cells was found to contain very small secretory granules in thier cytoplasm. These granular cells occupied 10 out of a total of 100 bFGF-immunopositive cells counted in random sections from the anterior pituitaries of 3 individuals. Most of them were polygonal or stellate in shape and contained granules, 80-100 nm in diameter, comprising a moderately electron-dense core tightly surrounded by a limiting membrane (Fig. 5a ). In the cytoplasm, Golgi apparatus and rough endoplasmic reticulum were moderately developed. The immunoreactivity was localized exclusively in the nucleus. One of the immunoreactive granular cells contained granules as small as 60 nm in diameter and poorly developed cell organelles (Fig. 5b) . Ultrastructurally, these immunopositive granular cells were similar to immature and intermediate type of endocrine cells (KuROSUMI, 1986 (KuROSUMI, , 1988 OZAWA and KUROSUMi, 1989) . On the other hand, the known mature types of endocrine cells with larger granules, 120-500 nm in diameter (KURosuMI, 1968; MORIARTY, 1973) , were all immunonegative for bFGF (Figs. 5a, b, 6a-c) .
No bFGF-immunoreactivity was recognized in the marginal layer (ML) cells (YOSHIMURA et al., 1977b) , which lined the anterior wall of the pituitary cleft and were immunopositive for S100 (Fig. 4) . Other elements in the anterior pituitary, including the capillary endothelium, interstitial fibroblasts and basal lamina, were devoid of the immunoreaction.
Intermediate lobe
In the intermediate lobe, bFGF-immunoreactivity was recognized in approximately half of the ML cells lining the posterior wall of the pituitary cleft (Figs. 1,  7a) . By immuno-electron microscopy, the reaction products were exclusively localized in the nuclei of immunopositive ML cells, which were characterized by their cuboidal shape, absence of cytoplasmic granules, and plentiful cilia protruding into the cleft (Fig.   7b ). No ultrastructural differences were recognized between the bFGF-immunopositive and bFGF-negative ML cells. Other cell types in the intermediate lobe were immunonegative for bFGF.
Neural lobe
The cells in the neural lobe, i.e., pituicytes, were completely immunonegative for bFGF (Fig. 1) , although they were immunoreactive for S100 (not shown; TSUCHIDA et al., 1991) .
DISCUSSION
To our knowledge, the present study has provided the first evidence of the immunohistochemical localization of bFGF in the FS cells, which is compatible with an in vitro observation of the cultured FS cells producing bFGF (FERRARA et al., 1987) . In contrast, several studies have documented the immunocytochemical localization of bFGF in various cell types of anterior pituitary, namely, the corticotroph (BAIRD et al., 1986) , all endocrine cells (GROTHE and UNSICKER, 1989) and gonadotroph (SCHECHTER and WEINER, 1991) . Although the reason for the variability of immunohistochemical results remains unlear, SCHECHTER and WEINER (1991) have postulated that it is probably related to the epitopes recognized by the different antibodies used and the conformational changes of bFGF occurring during its synthesis and transport. In this context, the monoclonal antibody bFM-1 used in the present study does not crossreact with denatured bFGF, whereas it inhibits the biological activity of bFGF. This suggests that bFM-1 recognizes the conformation of bFGF that is necessary for its biological activity (MATSUZAKI et al., 1989) . The present results, therefore, imply that bFGF with active conformation is present in the FS cell. In regard to the subcellular localization of bFGF, there are conflicting immunocytochemical results obtained from various pituitary and extra-pituitary cell types, both in vivo and in vitro. These include the cytoplasm (JANET et al., 1987; SCHECHTER and WEINER, 1991, AMANO et al., 1993) , nucleus (KARDAMI and FANDRICH, 1989; TESSLER and NEUFELD, 1990; SUZUKI et al., 1991) , and extracellular matrix (KARDAMI and FANDRICH, 1989; CORDON-CARDO et al., 1990; SCHECHTER and WEINER, 1991) . The present study has demonstrated bFGF-immunoreactivity localized primarily in the nuclei of FS cells in the anterior pituitary. Again, the discrepancy might be accounted for in terms of the epitope specificities of the different antibodies. However, recent studies have revealed that the alternative initiation of translation brings about several bFGF molecular species differing in molecular weight, which are located differentially in the cytoplasm or nucleus (RENKO et al., 1990; BUGLER et al., 1991) . Therefore, it is also possible that the subcellular localization of bFGF is regulated in a tissue-or cell type-specific manner. In support of this possibility, we recently demonstrated a cytoplasmic rather than nuclear localization of bFGF in a subset of rat salivary gland duct cells using the same monoclonal antibody bFM-1 (AMANO et al., 1993) . Although the mechanism of translocation of bFGF into the nucleus is not fully understood, the nuclear bFGF is considered to be responsible for the regulation of cell growth and differentiation at the transcriptional level (BOUCHE et al., 1987; BALDIN et al., 1990; NAKANISHI et al., 1992) . The present results may indicate that the FS cells produce bFGF which functions in thier own nuclei by an "intracrine" mechanism (NAKANISHI et al., 1992) . Alternative explanations, such as that FS cells secrete bFGF which functions in the neighboring cells by the paracrine/autocrine mechanism, and that bFGF derived from outside of FS cells targets FS cells, can not be ruled out. Studies designed to identify the cell types that actually express the genes for bFGF and/or its receptors will be required to clarify The biological role of the FS cell has not been determined. There is evidence that it exerts phagocytotic activity under certain experimental conditions (SHIOTANI, 1980; SHIRASAWA et al., 1983) . On the other hand, YOSHIMURA et al. (1977a) proposed that the FS cell serves as the stem cell of various endocrine cell types in the anterior pituitary, on the basis of their observation that the cell undergoes differentiation into a granulated cell under various experimental conditions. Furthermore, KAGAYAMA (1965) found, under normal conditions, small cytoplasmic granules in a subpopulation of the FS cell in dog pituitary. In the present study, we have found that a small subpopulation (10% in number) of the cells with nuclear immunoreactivity for bFGF in anterior pituitary possesses cytoplasmic granules that are smaller than those of any mature endocrine cell types. These lines of evidence lead to a hypothesis that the bFGF-positive granulated cells represent the transitional forms of FS cells into mature endocrine cells. A more detailed immunohistochemical study using antisera to different types of pituitary hormones combined with bFM-1 will be necessary to examine this hypothesis.
The ML cells of both anterior and intermediate lobi are considered to originate from the epithelial cells lining embryonic Rathke's pouch (ROMEIS,1940; KAGAYAMA et al., 1969) , and share with the FS cell many ultrastructural features and S100-immunoreactivity (KOBAYASHI, 1975; YOSHIMURA et al., 1977b; SHIRASAWA et al., 1983; INOUE et al., 1987) . However, the present results showing the bFGF-immunoreactivity in most of the FS cells, some of the intermediate lobe ML cells, and none of the anterior lobe ML cells, suggest that a functional heterogeneity exists among these cell populations.
The present observations have revealed that an epitope of bFGF is localized in the nuclei of subsets of agranular cells and immature endocine cells in rat pituitary gland. The biological significance of bFGF in these cell types, with reference to its role in the differentiation of pituitary endocrine cells, is yet to be determined.
